Phesi

Founded in 2007 and headquartered in Boston, Phesi operates at the intersection of AI/Machine Learning and Digital Health, offering a proprietary Trial Accelerator™ platform. The platform uses predictive modeling and digital twin technology to simulate clinical trials, generate digital patient profiles, and create external control arms, thereby de-risking and streamlining the clinical development process. Trusted by leading pharmaceutical companies like Sanofi and Takeda, Phesi's data-driven approach addresses critical inefficiencies in traditional trial design and execution. The company is privately held and appears to be revenue-generating, serving clients across over 4,000 disease indications.

Trial Accelerator™ platform: An AI-powered clinical trial intelligence platform built on a massive curated database of real-world clinical trial data. It enables predictive modeling, digital patient profiling, protocol simulation, and the creation of digital twins/external control arms to optimize trial design and execution.

Phesi competes in a fragmented market including large, diversified Contract Research Organizations (CROs) like IQVIA and Parexel, which offer analytics services; specialized clinical trial technology firms like Medidata and Veeva; and a growing cohort of AI-native startups focused on specific aspects of trial optimization, such as Unlearn.AI (digital twins) and Saama (AI analytics).